Stock BTPC ACTIVE BIOTECH AB
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Active Biotech AB Xetra

Equities

BTPC

SE0001137985

End-of-day quote Xetra
Other stock markets
- EUR - Intraday chart for Active Biotech AB
22/05 Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug MT
22/05 Active Biotech Enters into an Exclusive License Agreement with the Wistar Institute of Anatomy and Biology CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Number of shares and votes in Active Biotech
AQ
Clinical activity and safety of naptumomab and docetaxel to be presented at ASCO 2024
AQ
Annual General Meeting of Active Biotech AB
AQ
Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug
MT
Active Biotech acquires exclusive rights to patents of tasquinimod in combination therapy
AQ
Active Biotech Enters into an Exclusive License Agreement with the Wistar Institute of Anatomy and Biology
CI
Active Biotech : Interview with Prof. Dr. Axel Glasmacher, Independent Board Member at Active Biotech
PU
Active Biotech Q1 2024 - Approching Naptumomab Topline Data in Lung Cancer
AQ
Active Biotech Interim Report Q1 2024
AQ
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Annual Report 2023 Active Biotech AB (publ)
AQ
Active Biotech announces start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops
AQ
Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops
CI
Active Biotech Q4 2023 - Three Externally Funded Trials in 2024
AQ
Active Biotech Year End Report 2023
AQ
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Number of shares and votes in Active Biotech
AQ
Active Biotech provides update on the scheduled clinical program for 2024
AQ
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACTI Stock
  4. BTPC Stock
  5. News Active Biotech AB